Q-omics provides the consensus-scored MFSD2B profile across patient tissues and cancer cell-line models. MFSD2B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MFSD2B is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, MFSD2B RNA expression shows 16,467 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where MFSD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD2B survival associations across molecular data types. MFSD2B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD2B RNA expression–survival associations across cancer types. High MFSD2B expression shows unfavorable associations in ACC, KIRC, KIRP and UCEC, but favorable associations in CESC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MFSD2B RNA expression.
This table summarizes MFSD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MFSD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD2B shows higher tumor expression in COAD, LUAD, HNSC, THCA, LUSC and LIHC. The COAD box plot shows higher MFSD2B RNA expression in tumor versus normal tissue (log2 FC = +0.386, t-test p < 0.001).
This table shows molecular features associated with MFSD2B in patient tissues and cancer cell lines. In patient samples, MFSD2B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
